Netherlands· NL-aacde4b243ad
Eposin, concentraat voor oplossing voor infusie 20 mg/ml
A etoposide product containing etoposide, registered in Netherlands by Pharmachemie B.V.. The same ATC class is registered in 17 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Etoposide is registered in 17 of 19 countries.
Countries holding a registration under ATC L01CB01 (etoposide), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 10 of them publish a price we can compare per daily dose
Etoposide · ATC L01CB01
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of etoposide costs, country by country.
Normalised to the WHO defined daily dose (50 mg), the median price runs from $9.95 in France to $18.65 in Switzerland — a ×1.9 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Etoposide · price per daily dose (50 mg)
USD · FX 28 Sept 2026
- CH Switzerland$18.65
- FR France$9.95
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- ETOPOSIDE
- Manufacturer
- Pharmachemie B.V.
- Country
- Netherlands (NL)
- ATC code
- L01CB01
- ATC class
- Etoposide
- Defined daily dose
- 50 mg, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id16307
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
576 interactions on record for etoposide.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Etoposide · interactions on record
576 records
- 30 severe
- 290 moderate
- 21 minor
- 235 info
Most severe, free to view
- CladribineL01BB04severe
- AprepitantA04AD12moderate
- RolapitantA04AD14moderate
- EliglustatA16AX10moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Etoposide in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceETOPOSIDE ACCORD 20 mg/mL, solution à diluer pour perfusionACCORD HEALTHCARE FRANCE
- United KingdomEposin 100mg/5ml concentrate for solution for infusion vialsmedac UK
- United StatesAvopefAvyxa Pharma, LLC
- BelgiumCelltop 100 mgBaxter
- NorwayETO-cellStada
- FinlandEposinPCH Pharmachemie BV
- CzechiaETOPOSID EBEWEEBEWE Pharma Ges.m.b.H Nfg.KG, Unterach
- SwedenEposin 20 mg/ml Koncentrat till infusionsvätska, lösningTeva Sweden AB
Authorised across Europe · EMA
The same active substance is authorised in 28 EEA countries. Names it is sold under:
- Austria · Etoposid Accord, Etoposid Ebewe
- Belgium · Celltop, Eposin
- Bulgaria · Eтопозид Акорд
- Cyprus · Etoposide Accord
- Czechia · Etoposid Ebewe, Etoposide Accord
- Germany · Eto-Cell, Eto-Cell®
- Denmark · Etoposid Accord, Etoposid Ebewe
- Estonia · Etoposide Accord, Etoposide Kabi
- Spain · Etopósido Accord, Etopósido Hikma
- Finland · Etoposid Fresenius Kabi, Etoposide Accord
- France · Celltop, Etopophos
- United Kingdom (Northern Ireland) · Etopophos, Etoposide
- Greece · Etobion
- Croatia · Etoposide Sandoz
- Hungary · Etoposid Sandoz, Etoposide Accord
- Ireland · Etoposide, Etoposide Accord Healthcare
- Iceland · Etópósíð Accord
- Italy · Etoposide Accord, Etoposide Hikma
- Lithuania · Etoposid Ebewe, Etoposide Accord
- Luxembourg · Eposin, Etoposide Accord Healthcare
- Latvia · Etoposide Accord, Etoposide Ebewe
- Norway · Etoposid Ebewe, Etoposid Fresenius Kabi
- Poland · Etoposid Ebewe, Etopozyd Accord
- Portugal · Etoposido Accord, Etoposido Hikma
- Romania · Etoposid Accord, Etoposide Teva
- Sweden · Eposin, Etopofos
- Slovenia · Ebeposid, Eposin
- Slovakia · Etoposid Sandoz, Etopozid Accord
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e5d9f9cc-5022-4298-bc9f-a74d4e7b51d5 GET /v1/drugs/e5d9f9cc-5022-4298-bc9f-a74d4e7b51d5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentraat voor oplossing voor infusie",
"route": "Intraveneus gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h16307_smpc.pdf",
"strength": null,
"atc_label": "Etoposide",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg16307",
"excipients": [
"BENZYLALCOHOL (E 1519)",
"CITROENZUUR 0-WATER (E 330)",
"ETHANOL",
"MACROGOL 300",
"POLYSORBAAT 80 (E 433)"
],
"substances": [
"ETOPOSIDE"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h16307.pdf",
"authorised_at": "1994/09/28",
"procedure_number": "NL/H/0120/001",
"dispensing_status": "Uitsluitend recept",
"registration_number": "16307",
"additional_monitoring": "N"
}See everything about etoposide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.